Human type antihuman IgE receptor antibody and fragment
View Patent ↗An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.
1. A human anti-human Fcε receptor I (hereinafter referred to as “FcεRI”) antibody or an antibody fragment thereof that binds to a human FcεRI and has an activity to inhibit the binding between the FcεRI and IgE and that is prepared by the genetic recombination technique with an expression vector in which the following gene fragments are incorporated;
a) a gene fragment encoding VH chain of the human anti-human FcεRI antibody, wherein complimentary determining regions (CDR1 to CDR3) in said VH chain have the following amino acid sequences;
CDR1: Ser Asn Tyr Met Ser (SEQ ID NO: 5);
CDR2: Val Ile Tyr Arg Gly Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Gly Ser Val Lys Gly (SEQ ID NO: 6);
CDR3: Ser Ser Asp Val Gly Tyr Gly Ile Leu Arg Gly Tyr Met Asp Val (SEQ ID NO: 7), and
b) a gene fragment encoding VL chain of the human anti-human FcεRI antibody, wherein complementary determining regions (CDR1 to CDR3) in said VL chain have the following amino acid sequences;
CDR1: Ser Gly Gln Asp Leu Thr Asn Lys Tyr Val Ser (SEQ ID NO: 8);
CDR2: Glu Asp Ser Lys Arg Pro Ser (SEQ ID NO: 9);
CDR3: Gln Ala Tyr Asp Thr Asn Gly Trp Val (SEQ ID NO: 10)
2. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein said VH chain gene consists of a nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 2, and said VL chain gene consists of a nucieotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 4.
3. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein a single-chain Fv gene comprising said gene fragment encoding VH chain bound to said gene fragment encoding VL chain is incorporated in the expression vector.
4. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein said gene fragment encoding VH chain and said gene fragment encoding VL chain are bound to a human antibody CH chain gene and a human antibody CL chain gene, respectively.
5. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein said gene fragment encoding VH chain and said gene fragment encoding VL chain are bound to a human antibody CH chain gene or a portion thereof and a human antibody CL chain gene or a portion thereof, respectively.
6. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein said antibody fragment is selected from Fab, Fab', or F (ab') 2 .
7. The human anti-human FcεRI antibody or the antibody fragment thereof of claim 1 wherein a single-chain Fv gene comprising said gene fragment encoding VH chain bound to said gene fragment encoding VL chain is incorporated in the expression vector, said single-chain Fv gene being bound to a human antibody CH chain gene or a portion thereof or a human antibody CL chain gene or a portion thereof.
8. An inhibitor to the IgE-IgE receptor binding comprising the human anti-IgE receptor antibody or the human anti-IgE receptor antibody fragment of claim 1 .
9. A medicament for treating allergic diseases comprising the human anti-IgE receptor antibody fragment of claim 1 , wherein said antibody fragment is in the form of scFv, Fab or Fab'.